Exelixis, Inc. (EXEL) vs Summit Therapeutics Inc. (SMMT)

A side-by-side comparison of Exelixis, Inc. and Summit Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Exelixis, Inc. logo
EXEL
Exelixis, Inc.
$14.66B
$58.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Summit Therapeutics Inc. logo
SMMT
Summit Therapeutics Inc.
$13.81B
$17.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — EXEL vs SMMT

growth of $100 · dividends reinvested · last 10y
EXEL +346.5% (+16.1%/yr)SMMT +29.2% (+2.6%/yr)EXEL compounded faster over this window
0100200300400Start $10020182020202220242026$447$129
EXEL SMMT

EXEL vs SMMT: by the numbers

  • •EXEL is the larger company ($14.66B vs $13.81B market cap).
  • •EXEL is profitable (35.33% net margin) while SMMT runs a net loss (0.00%).

Metrics side by side

Valuation

MetricEXELSMMT
P/E ratio18.29N/A
Forward P/E16.61N/A
PEG ratio0.36N/A
P/S ratio6.02N/A
P/B ratio7.9521.92
EV / EBITDA14.55N/A
FCF yield7.90%N/A

Profitability

MetricEXELSMMT
Gross margin96.48%0.00%
Operating margin39.88%0.00%
Net margin35.33%0.00%
ROE46.68%-135.89%
ROIC37.87%-134.14%

Growth (annualized)

MetricEXELSMMT
Revenue CAGR (5Y)16.06%N/A
EPS CAGR (5Y)51.51%N/A
FCF CAGR (5Y)39.63%N/A
Total return CAGR (5Y)23.00%28.09%

Frequently asked

Is EXEL or SMMT more profitable?
EXEL runs the higher net margin — EXEL at 35.33% versus SMMT at 0.00%.
How have EXEL and SMMT total returns compared?
Over the past 10 years, EXEL delivered 16.20% and SMMT delivered 1.87% annualized total return. Past performance doesn't predict future results.

Go deeper

Full EXEL analysisFull SMMT analysisInteractive comparison tool

Dig into the metrics

Exelixis P/E ratioExelixis ROESummit Therapeutics ROEExelixis operating marginSummit Therapeutics operating marginExelixis revenue growthSummit Therapeutics revenue growthExelixis free cash flowSummit Therapeutics free cash flow

Exelixis & Summit Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksHighest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.